September 2026– date –
-
Made Scientific: 85,000 sq-ft cell therapy facility acquisition
Contract Pharma USA Overview Made Scientific has acquired an 85,000 square-foot cell therapy manufacturing facility in East Norriton, Pennsylvania, from National Resilience. The facility, designed for clinical development through commerc... -
FDA vs EMA: CGT manufacturing and potency assay requirements
Rhizome AI USA Overview Significant structural differences exist between FDA and EMA manufacturing controls and GMP requirements for Cell and Gene Therapy (CGT) at the IND/CTA stage. The FDA maintains more explicit early-stage requiremen... -
Ryoncil: Mesoblast’s new FDA potency assay specs for GVHD drug
Mugglehead Australia Overview Mesoblast has received FDA approval for a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for Ryoncil (remestemcel-L), its treatment for pediatric steroid-refractory acute Graft-versu... -
iPSC Cell Therapy: 2026 roadmap for BeiGene, BlueRock and Fate
BioInformant USA Overview As of 2026, leading companies such as BeiGene, BlueRock Therapeutics, and Fate Therapeutics are actively advancing diverse pipelines of iPSC-derived cell therapeutics. Notably, Fate Therapeutics has secured FDA ... -
NVIDIA Isaac ROS 5.0: FoundationPose 5.5x speedup explained
NVIDIA Technical Blog USA Overview NVIDIA has released Isaac ROS 5.0, enhancing the ability of robot developers to build agent-enabled open-source robotics applications. The new version features "FoundationPose," a foundational model tha... -
ISM001-055: Phase 2a clinical trial specs for TNIK inhibitor
Brieflands USA Overview The small molecule TNIK inhibitor rentosertib (formerly ISM001-055/INS018_055), discovered and designed using a generative AI approach, is being evaluated in a randomized Phase 2a clinical trial for idiopathic pul... -
Stanford Biotech: 37,000 AI agents’ drug discovery roadmap
Stanford Medicine USA Overview An AI-powered virtual biotech company, spun out of a Stanford Medicine lab, is deploying 37,000 AI agents across the entire drug discovery pipeline, dramatically accelerating the prediction of high-potentia... -
ASCEND: NHTSA and SAE’s 2026 self-driving safety specs
GeekNewz USA Overview The National Highway Traffic Safety Administration (NHTSA) and SAE International have jointly launched ASCEND, a new consortium to define data-driven performance standards for Automated Driving Systems (ADS). ASCEND... -
AI Drug Discovery: Phase I vs Phase II success rates in 2026
World Health Expo Unknown Overview AI is accelerating drug discovery, leveraging tools like AlphaFold for protein structure prediction and generative models for novel molecule design. While AI-discovered candidates achieve 80-90% success... -
Teradata Agentic AI: Q4 2026 launch timeline and cost specs
TradingView News USA Overview Teradata announced the Q4 2026 launch of a new agentic AI platform poised to revolutionize enterprise data automation and AI agent utilization. Benchmarking shows the platform delivers a groundbreaking 58% l...
